Almonds and the gut: butyrate rose, the primary endpoint did not
A four-week trial separated a fecal butyrate change from null findings for bifidobacteria, transit and symptoms.

Illustrative food image, not a photograph of the study intervention.
Three assignments and a named primary outcome
Eighty-seven healthy adults entered a three-arm randomized trial comparing whole almonds, ground almonds and an isocaloric control in place of habitual snacks. Both almond assignments supplied 56 grams daily for four weeks. The primary outcome was fecal bifidobacteria, with other measurements covering microbiota composition, short-chain fatty acids, transit, stool output and symptoms. The modified intention-to-treat analysis included 79 participants. Keeping the primary endpoint visible is important: a favorable secondary measurement should not silently replace the question the investigators originally identified. This was also a study in healthy adults, rather than a trial treating a diagnosed bowel disorder.
Creedon AC, Dimidi E, Hung ES, Rossi M et al.. The American journal of clinical nutrition, 2022. PMID 36130222 · DOI
Bifidobacteria did not significantly differ
The average fecal bifidobacteria abundance was 8.7% after whole almonds, 7.8% after ground almonds and 13.0% after the control assignment. The reported q value was 0.613, and the abstract states that the groups did not differ significantly. Almond consumption also had no effect on microbiota diversity or composition at the phylum level. These findings do not support a headline saying that almonds broadly increased beneficial bacteria or expanded microbial diversity in this trial. The study's interesting positive signal appeared in a different measurement, which deserves to be described separately rather than used to erase the primary null result.
Creedon AC, Dimidi E, Hung ES, Rossi M et al.. The American journal of clinical nutrition, 2022. PMID 36130222 · DOI
Butyrate was higher in the pooled comparison
When the whole and ground almond groups were pooled, mean fecal butyrate was 24.1 micromoles per gram, compared with 18.2 in the control group, with P equal to 0.046. Standard deviations were 15.0 and 9.1 micromoles per gram, respectively. That is a specific fecal measurement rather than a demonstrated improvement in how participants felt. The abstract reports no almond effect on gut transit time, stool consistency or gut symptoms. Together, those results support describing a butyrate signal without claiming that almonds relieved constipation, accelerated transit or improved gastrointestinal comfort in these healthy participants.
Creedon AC, Dimidi E, Hung ES, Rossi M et al.. The American journal of clinical nutrition, 2022. PMID 36130222 · DOI
Grinding changed particles, not the clinical findings
Almond form did not change the study outcomes. In the additional processing assessment involving 31 participants, ground almonds produced smaller particle sizes and higher predicted lipid release: 10.4% compared with 9.3% for whole almonds, with P equal to 0.017. Predicted release is the endpoint reported there, not a measured advantage for bowel symptoms or microbiota diversity. The four-week duration and healthy-adult population also limit wider interpretation. The most balanced conclusion remains that almonds had limited effects on microbial composition while increasing fecal butyrate in the pooled comparison. An almond recipe is not a replication of either experimental snack assignment.
Creedon AC, Dimidi E, Hung ES, Rossi M et al.. The American journal of clinical nutrition, 2022. PMID 36130222 · DOI